| Budget Amount *help |
¥27,820,000 (Direct Cost: ¥21,400,000、Indirect Cost: ¥6,420,000)
Fiscal Year 2010: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2009: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2008: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
|
|---|
| Research Abstract |
It is essential to develop effective immunoadjuvants for tumor immunotherapy. We created new adjuvants based on the structure of mycoplasmal lipopeptide, which is a toll-like receptor (TLR) 2 ligand. Adjuvant engineering, substituting a functional motif for bacterial origin sequence of lipopeptide, is our novel drug design strategy. We succeeded in development of useful synthetic adjuvants through the evaluation of new TLR2 ligands with additional functions such as targeting ability to immune cells or modification ability to tumor cells.
|
